Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation
Authors
Keywords
-
Journal
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Volume 19, Issue 8, Pages 1874-1882
Publisher
Wiley
Online
2021-07-14
DOI
10.1111/jth.15358
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
- (2021) Alexander Cohen et al. Journal of Clinical Medicine
- Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism
- (2020) James C. Coons et al. PHARMACOTHERAPY
- Evidence of impaired dabigatran absorption following laparoscopic Roux‐en‐Y gastric bypass surgery: the Auckland regional experience (2011–2018)
- (2020) Brian Grainger et al. BRITISH JOURNAL OF HAEMATOLOGY
- Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight
- (2020) Waldemar E. Wysokinski et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Fixed dose rivaroxaban can be used in extremes of bodyweight: a population pharmacokinetic analysis
- (2020) Victoria Speed et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis
- (2020) Mohamed Nabil Elshafei et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data
- (2020) Olivia S. Costa et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Direct Oral Anticoagulant Concentrations in Obese and High Body Weight Patients: A Cohort Study
- (2020) Anne Céline Martin et al. THROMBOSIS AND HAEMOSTASIS
- Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data
- (2019) Margarita Kushnir et al. Lancet Haematology
- Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight
- (2019) Isaac J. Perales et al. ANNALS OF PHARMACOTHERAPY
- Validation of apixaban anti-factor Xa assay and impact of body weight
- (2019) Suman M. Wasan et al. THROMBOSIS RESEARCH
- Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs
- (2019) Alex C. Spyropoulos et al. THROMBOSIS RESEARCH
- Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119)
- (2018) L. Tittl et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects
- (2018) Wonkyung Byon et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The effect of bariatric surgery on direct-acting oral anticoagulant drug levels
- (2018) Amihai Rottenstreich et al. THROMBOSIS RESEARCH
- The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study
- (2018) Dino Kröll et al. Surgery for Obesity and Related Diseases
- Obesity and cardiovascular disease: revisiting an old relationship
- (2018) Chrysi Koliaki et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs)
- (2017) Hakeam A. Hakeam et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
- (2017) Jeffrey I. Weitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antithrombotic Therapy for VTE Disease
- (2016) Clive Kearon et al. CHEST
- Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
- (2016) K. Martin et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Treatment of venous thromboembolism with rivaroxaban in relation to body weight
- (2016) Maria C. Vedovati et al. THROMBOSIS AND HAEMOSTASIS
- Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience
- (2016) DRJ Arachchillage et al. THROMBOSIS RESEARCH
- Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics
- (2016) Sophie Testa et al. THROMBOSIS RESEARCH
- Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: A meta-analysis of randomized controlled trials
- (2015) Matteo Nicola Dario Di Minno et al. ANNALS OF MEDICINE
- Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in overweight and obese postarthroplasty patients
- (2015) Ranjan Pathak et al. BLOOD COAGULATION & FIBRINOLYSIS
- Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule
- (2015) Dolly A. Parasrampuria et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Real-world variability in dabigatran levels in patients with atrial fibrillation: reply
- (2015) N. C. Chan et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
- (2015) Christian T Ruff et al. LANCET
- Population Pharmacokinetics and Dose–Exposure Proportionality of Edoxaban in Healthy Volunteers
- (2014) Ophelia Q. P. Yin et al. CLINICAL DRUG INVESTIGATION
- Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
- (2013) Vijay V. Upreti et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients
- (2013) Paul A. Reilly et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels
- (2013) E. M. Hawes et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Pharmacokinetics of rivaroxaban after bariatric surgery: a case report
- (2013) Adrian Mahlmann et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups
- (2012) G. F. PINEO et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Apixaban for Extended Treatment of Venous Thromboembolism
- (2012) Giancarlo Agnelli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: A pooled analysis
- (2012) Bengt I. Eriksson et al. THROMBOSIS RESEARCH
- Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty
- (2010) Michael Rud Lassen et al. THROMBOSIS AND HAEMOSTASIS
- Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery
- (2009) Wolfgang Mueck et al. CLINICAL PHARMACOKINETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started